Clinical Trial Update: Tobramycin Inhalation Solution Administered by eFlow Rapid Nebulizer: Scintigraphy Study [Phase 1]

View source ↗

Summary

Phase 1 scintigraphy study evaluating the distribution of inhaled tobramycin delivered by the eFlow Rapid Nebulizer in cystic fibrosis patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• TOBI (tobramycin) inhalation solution (tobramycin)

Snippet

Sponsor: Novartis | Conditions: Cystic Fibrosis | Phase 1 | Status: COMPLETED